Literature DB >> 7955452

Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism.

A H Mudde1, A J Houben, A C Nieuwenhuijzen Kruseman.   

Abstract

OBJECTIVE: There is recent evidence that both exogenous and endogenous subclinical thyrotoxicoses are associated with decreased bone mineral density. Scanty information is available on bone metabolism in these conditions when euthyroidism is restored. We evaluated the effect of anti-thyroid drug treatment on bone metabolism in endogenous subclinical hyperthyroidism.
DESIGN: Prospective follow-up study over 2 years during treatment with methimazole, with an untreated control group.
SUBJECTS: Sixteen post-menopausal women with endogenous subclinical hyperthyroidism associated with multinodular goitre, eight of whom were treated with methimazole. MEASUREMENTS: Serum concentrations of free T4, total T3, TSH, osteocalcin, urinary excretion of hydroxyproline and forearm bone mineral density were measured at regular intervals.
RESULTS: Significant changes in serum osteocalcin concentration or urinary hydroxyproline excretion were not observed in either group. Distal, but not proximal, forearm bone mineral density, expressed as a percentage of the base-line value, was significantly (P < 0.05) higher in the treated than in the untreated subjects in the second year of treatment.
CONCLUSION: Treatment with methimazole in post-menopausal women with endogenous subclinical hyperthyroidism associated with multinodular goitre can prevent excessive loss of bone, at least in the distal forearm.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955452     DOI: 10.1111/j.1365-2265.1994.tb02571.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

Review 1.  Thyroid dysfunction in the elderly.

Authors:  Kristien Boelaert
Journal:  Nat Rev Endocrinol       Date:  2013-02-26       Impact factor: 43.330

Review 2.  Subclinical hyperthyroidism: to treat or not to treat?

Authors:  E H Hoogendoorn; M den Heijer; A P J van Dijk; A R Hermus
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

Review 3.  Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis.

Authors:  Christina D Wirth; Manuel R Blum; Bruno R da Costa; Christine Baumgartner; Tinh-Hai Collet; Marco Medici; Robin P Peeters; Drahomir Aujesky; Douglas C Bauer; Nicolas Rodondi
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391

4.  Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism.

Authors:  S Buscemi; S Verga; S Cottone; G Andronico; L D'Orio; V Mannino; D Panzavecchia; F Vitale; G Cerasola
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

Review 5.  Subclinical thyroid disease.

Authors:  J W Elte; A H Mudde; A C Nieuwenhuijzen Kruseman
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

6.  The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.

Authors:  Bernadette Biondi; Luigi Bartalena; David S Cooper; Laszlo Hegedüs; Peter Laurberg; George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-08-26

Review 7.  Bone disease in thyrotoxicosis.

Authors:  P Amaresh Reddy; C V Harinarayan; Alok Sachan; V Suresh; G Rajagopal
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

8.  Management of subclinical hyperthyroidism.

Authors:  Silvia Santos Palacios; Eider Pascual-Corrales; Juan Carlos Galofre
Journal:  Int J Endocrinol Metab       Date:  2012-04-20

Review 9.  Thyrotropin, Hyperthyroidism, and Bone Mass.

Authors:  Se-Min Kim; Vitaly Ryu; Sari Miyashita; Funda Korkmaz; Daria Lizneva; Sakshi Gera; Rauf Latif; Terry F Davies; Jameel Iqbal; Tony Yuen; Mone Zaidi
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

10.  A Modest Protective Effect of Thyrotropin against Bone Loss Is Associated with Plasma Triiodothyronine Levels.

Authors:  Tae Hyuk Kim; Ji Young Joung; Mira Kang; Sun Kyu Choi; Kyunga Kim; Ju Young Jang; Yoon Young Cho; Yong-Ki Min; Jae Hoon Chung; Sun Wook Kim
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.